Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report 2026

The gonadotropin-releasing hormone (gnrh) agonist market size has grown steadily in recent years. It will grow from $4.19 billion in 2025 to $4.29 billion in 2026 at a compound annual growth rate (CAGR) of 2.4%. The growth in the historic period can be attributed to growth of IVF procedures, prostate cancer treatment adoption, hormone therapy development, hospital endocrinology expansion, injectable drug innovation.

The gonadotropin-releasing hormone (gnrh) agonist market size is expected to see steady growth in the next few years. It will grow to $4.73 billion in 2030 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to rising infertility rates, oncology treatment demand, long-acting implant development, improved reproductive healthcare access, specialty clinic growth. Major trends in the forecast period include increased use in fertility treatments, growing application in hormone-related cancers, expansion of long-acting drug formulations, rising demand for assisted reproductive technologies, improved hormonal disorder management.

The rising prevalence of hormone-related diseases is expected to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders are medical conditions resulting from imbalances or dysfunctions in the endocrine system, which produces and regulates hormones. These disorders include conditions such as diabetes, hyperthyroidism, and prostate cancer. The increasing incidence of hormone-related diseases is influenced by factors such as environmental exposure, obesity and metabolic syndrome, genetics, and the aging population. GnRH agonists help carefully regulate hormone levels, providing a targeted approach to managing conditions associated with hormonal imbalances. For example, in June 2024, the National Health Service, a UK-based government department, reported that in 2023, over half a million (549,000) additional individuals in England were identified as at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a nearly 20% increase from 3,065,825 in 2022, highlighting the growing burden of hormone-related conditions. Therefore, the rising prevalence of hormone-related diseases is driving the gonadotropin-releasing hormone (GnRH) agonist market.

Major companies in the gonadotropin-releasing hormone (GnRH) agonist market are focusing on developing advanced androgen deprivation therapy (ADT) drugs to improve treatment effectiveness and precision for hormone-sensitive cancers. ADT drugs, including GnRH analogs, work by reducing or eliminating androgen levels to slow or stop the growth of hormone-sensitive cancers. For instance, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Relugolix under the brand name Rexigo. This is India’s first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. Rexigo contains the globally recognized active ingredient Relugolix, providing rapid testosterone suppression. It is also 50% more affordable than existing injectable alternatives in India, representing a significant advancement in prostate cancer care by offering a safe, effective, and convenient option for patients and healthcare providers.

In June 2024, Kissei Pharmaceutical Co., Ltd., a Japan-based biopharmaceutical company, partnered with JW Pharmaceutical Corporation to develop and commercialize Linzagolix, a GnRH antagonist, in Korea. This collaboration aims to bring Linzagolix to the Korean market by leveraging Kissei’s expertise in GnRH therapies and JW Pharmaceutical’s local development, regulatory, and commercialization capabilities. JW Pharmaceutical Corporation is a South Korea-based company specializing in the development, manufacturing, and marketing of innovative therapeutics.

Major companies operating in the gonadotropin-releasing hormone (gnrh) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., AstraZeneca plc, Merck KGaA, Sumitomo Pharma Co Ltd, Gedeon Richter Plc, Myovant Sciences Ltd.

North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2025. The regions covered in the gonadotropin-releasing hormone (gnrh) agonist market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gonadotropin-releasing hormone (gnrh) agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the GnRH agonist market by increasing costs of imported hormone formulations, implants, and injectable drug components. Hospitals and fertility clinics are most affected due to dependence on imported therapies. These tariffs raise treatment costs by increasing pricing for long-acting hormonal therapies used in fertility treatment, oncology, and endocrine disorders, impacting patient affordability. However, they encourage local pharmaceutical production, supporting domestic formulation and manufacturing of hormone-based therapies.

The gonadotropin-releasing hormone (gnrh) agonist market research report is one of a series of new reports that provides gonadotropin-releasing hormone (gnrh) agonist market statistics, including gonadotropin-releasing hormone (gnrh) agonist industry global market size, regional shares, competitors with a gonadotropin-releasing hormone (gnrh) agonist market share, detailed gonadotropin-releasing hormone (gnrh) agonist market segments, market trends and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (gnrh) agonist industry. This gonadotropin-releasing hormone (gnrh) agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gonadotropin-releasing hormone (GnRH) agonists are synthetic compounds that mimic the action of natural GnRH, which stimulates the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agonists help manage hormonal imbalances by regulating hormone levels and are particularly used in fertility treatments to control and prevent premature ovulation during procedures such as in vitro fertilization.

The main types of gonadotropin-releasing hormone (GnRH) agonists include leuprorelin, goserelin, taltirelin, histrelin, and others. Leuprorelin is a synthetic hormone used to treat conditions such as prostate cancer, endometriosis, and uterine fibroids by reducing hormone production, and it is administered through monthly or quarterly injections. It is available in various formulations, including injectables, implants, oral forms, and nasal sprays, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Leuprorelin is applied in multiple indications, including prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty, fertility treatment, and more, and is utilized by end users such as hospitals, specialty clinics, ambulatory surgical centers (ASCs), and others.

The gonadotropin-releasing hormone (GnRH) agonists market consists of sales of triptorelin, buserelin, and nafarelin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.